Nektar Therapeutics says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD

Nektar reported new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis, presented at EADV Congress 2026, and said the results underpin a Phase 3 plan.